1. history of clinically significant allergic reactions. 2. hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. 3. anticipated transfer to another hospital which is not a study centre within the next 72 hours. 4. acute or chronic renal failure. 5. history of hiv infection, tuberculosis. 6. conditions associated with primary immunodeficiency. 7. concomitant use of cytostatic medications to treat a concomitant disease. 8. systemic connective tissue diseases. 9. need for the prohibited medications. 10. administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. 11. history of alcohol or drug dependence. 12. history of malignant tumours of any location with remission for less than 2 years. 13. history of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. 14. pregnancy or breastfeeding. 15. intravenous injections and/or sampling of the required amount of blood is not possible. 16. positive pregnancy test (in patients with childbearing potential). 17. participation in any clinical study within 3 months before enrolment in this study. 18. history of any condition that the study doctor considers significant enough to prevent enrolment of this patient.

1. history of clinically significant allergic reactions. 2. hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. 3. anticipated transfer to another hospital which is not a study centre within the next 72 hours. 4. acute or chronic renal failure. 5. history of hiv infection, tuberculosis. 6. conditions associated with primary immunodeficiency. 7. concomitant use of cytostatic medications to treat a concomitant disease. 8. systemic connective tissue diseases. 9. need for the prohibited medications. 10. administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. 11. history of alcohol or drug dependence. 12. history of malignant tumours of any location with remission for less than 2 years. 13. history of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. 14. pregnancy or breastfeeding. 15. intravenous injections and/or sampling of the required amount of blood is not possible. 16. positive pregnancy test (in patients with childbearing potential). 17. participation in any clinical study within 3 months before enrolment in this study. 18. history of any condition that the study doctor considers significant enough to prevent enrolment of this patient.

history of clinically significant allergic reactions. hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. anticipated transfer to another hospital which is not a study centre within the next 72 hours. acute or chronic renal failure. history of hiv infection, tuberculosis. conditions associated with primary immunodeficiency. concomitant use of cytostatic medications to treat a concomitant disease. systemic connective tissue diseases. need for the prohibited medications. administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. history of alcohol or drug dependence. history of malignant tumours of any location with remission for less than 2 years. history of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. pregnancy or breastfeeding. intravenous injections and/or sampling of the required amount of blood is not possible. positive pregnancy test (in patients with childbearing potential). participation in any clinical study within 3 months before enrolment in this study. history of any condition that the study doctor considers significant enough to prevent enrolment of this patient.

history of clinically significant allergic reactions. hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. anticipated transfer to another hospital which is not a study centre within the next 72 hours. acute or chronic renal failure. history of hiv infection, tuberculosis. conditions associated with primary immunodeficiency. concomitant use of cytostatic medications to treat a concomitant disease. systemic connective tissue diseases. need for the prohibited medications. administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. history of alcohol or drug dependence. history of malignant tumours of any location with remission for less than 2 years. history of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. pregnancy or breastfeeding. intravenous injections and/or sampling of the required amount of blood is not possible. positive pregnancy test (in patients with childbearing potential). participation in any clinical study within 3 months before enrolment in this study. history of any condition that the study doctor considers significant enough to prevent enrolment of this patient.

1. history of clinically significant allergic reactions. 2. hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. 3. anticipated transfer to another hospital which is not a study centre within the next 72 hours. 4. acute or chronic renal failure. 5. history of hiv infection, tuberculosis. 6. conditions associated with primary immunodeficiency. 7. concomitant use of cytostatic medications to treat a concomitant disease. 8. systemic connective tissue diseases. 9. need for the prohibited medications. 10. administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. 11. history of alcohol or drug dependence. 12. history of malignant tumours of any location with remission for less than 2 years. 13. history of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. 14. pregnancy or breastfeeding. 15. intravenous injections and/or sampling of the required amount of blood is not possible. 16. positive pregnancy test (in patients with childbearing potential). 17. participation in any clinical study within 3 months before enrolment in this study. 18. history of any condition that the study doctor considers significant enough to prevent enrolment of this patient.

1. history of clinically significant allergic reactions. 2. hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo. 3. anticipated transfer to another hospital which is not a study centre within the next 72 hours. 4. acute or chronic renal failure. 5. history of hiv infection, tuberculosis. 6. conditions associated with primary immunodeficiency. 7. concomitant use of cytostatic medications to treat a concomitant disease. 8. systemic connective tissue diseases. 9. need for the prohibited medications. 10. administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date. 11. history of alcohol or drug dependence. 12. history of malignant tumours of any location with remission for less than 2 years. 13. history of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders. 14. pregnancy or breastfeeding. 15. intravenous injections and/or sampling of the required amount of blood is not possible. 16. positive pregnancy test (in patients with childbearing potential). 17. participation in any clinical study within 3 months before enrolment in this study. 18. history of any condition that the study doctor considers significant enough to prevent enrolment of this patient.